Enveric Files 8-K Furnishing Q2 Results; See Exhibit 99.1

Rhea-AI Filing Summary

Enveric Biosciences furnished a press release providing a corporate update and announcing financial results for the quarter ended June 30, 2025, which is attached as Exhibit 99.1 to this Current Report on Form 8-K. The filing also includes a machine-readable Interactive XBRL cover page (Exhibit 104). The Form states the press release and related information are furnished, not filed, and therefore are not subject to Section 18 liability or automatically incorporated by reference into future registration statements except by specific reference.

No numerical financial figures or earnings tables are included in the body of the Form 8-K itself; the substantive financial results are contained in the furnished press release. The filing is signed by Chief Executive Officer Joseph Tucker, Ph.D.

Positive

• Press release furnished (Exhibit 99.1) announcing a corporate update and Q2 results, making the company’s update publicly available
• Interactive XBRL cover page (Exhibit 104) was included, supporting machine-readable data access

Negative

• No financial figures or earnings tables are included in the body of the Form 8-K, preventing assessment from the filing alone
• Information is furnished, not filed, which limits Section 18 liability and may affect incorporation by reference into future filings

Insights

Financial Analyst

TL;DR: Routine Form 8-K furnishing a press release with Q2 results; material impact cannot be assessed from this filing alone.

The company has furnished a press release announcing second-quarter financial results and a corporate update and included an Interactive XBRL cover page. The filing explicitly states the materials are furnished, not filed, which limits the legal status of the disclosure. Because this 8-K does not include the actual financial figures in-line, investors and analysts must review Exhibit 99.1 to evaluate revenue, profitability, cash position, and other metrics before assessing financial impact.

Corporate Governance Expert

TL;DR: The filing is procedural and clarifies legal treatment of the press release; it does not itself change governance or financial statements.

The company has followed routine disclosure practice by furnishing a press release and providing an XBRL cover page. The explicit statement that the information is furnished rather than filed reduces exposure to Section 18 liability and limits automatic incorporation by reference into future SEC filings. The filing is executed by the CEO, indicating appropriate signatory authority, but it contains no governance changes, officer departures, or other corporate actions.

false 0000890821 0000890821 2025-08-14 2025-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

August 14, 2025

Date of Report (Date of earliest event reported)

Enveric Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38286		95-4484725
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

Enveric Biosciences, Inc.

4851 Tamiami Trail N, Suite 200

Naples, FL 34103

(Address of principal executive offices) (Zip code)

Registrant’s telephone number, including area code: (239) 302-1707

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.01 per share		ENVB		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2025, Enveric Biosciences, Inc. issued a press release providing a corporate update and announcing its financial results for the second quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release, dated August 14, 2025 (furnished pursuant to Item 2.02)
104		Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 14, 2025	ENVERIC BIOSCIENCES, INC.
	By:	/s/ Joseph Tucker
		Joseph Tucker, Ph.D.
		Chief Executive Officer

FAQ

What did Enveric (ENVB) file in this Form 8-K?

Answer: The company furnished a press release providing a corporate update and announcing financial results for the quarter ended June 30, 2025, attached as Exhibit 99.1, and included an Interactive XBRL cover page (Exhibit 104).

Does this 8-K include detailed financial results for ENVB?

Answer: No. The Form 8-K states the press release is furnished; the filing itself does not contain numerical financial tables or earnings figures.

Is the furnished press release considered "filed" with the SEC?

Answer: The filing explicitly states the information furnished under Item 2.02 is not deemed to be “filed” for purposes of Section 18 of the Exchange Act.

Where can investors find the substantive financial information referenced in this 8-K?

Answer: Investors should review Exhibit 99.1 attached to the Form 8-K, which contains the press release with the corporate update and financial results.

Who signed the Form 8-K for Enveric (ENVB)?

Answer: The Form 8-K is signed by Joseph Tucker, Ph.D., Chief Executive Officer of Enveric Biosciences.